Abstract Objective Cytochrome P450 2C9 and 2C19 (CYP2C9 and CYP2C19, respectively)
genetic polymorphisms play an important role in phenytoin (PHT) metabolism. We have …

Background: Genetic polymorphisms of CYP2C9 can lead to wide inter-individual variations
in drug metabolism. Decreased metabolism leads to higher plasma levels, causing adverse …

Phenytoin (PHT) is an antiepileptic drug widely used in the treatment of focal epilepsy and
status epilepticus, and effective in controlling focal seizures with and without tonic–clonic …

Phenytoin has a widespread use in epilepsy treatment and is mainly metabolized by hepatic
cytochrome P450 enzymes (CYP). We have investigated CYP2C9* 2, CYP2C9* 3 …

Background and purpose: It is widely acknowledged that individual response to antiepileptic
drugs (AEDs) is influenced by genetic factors. However, most of the underlying genes and …

The objective of this study was to study the effect of CYP2C9 genetic polymorphism and
undernourishment on free phenytoin concentrations in epileptic patients. The study was …

Pharmacogenetic studies have shown that genetic defects in drug-metabolizing enzymes
encoded by CYP2C9, CYP2C19 genes and by the transporter ABCB1 gene can influence …

OBJECTIVE: CYP2C9 is a major enzyme in human drug metabolism and the polymorphism
observed in the corresponding gene may affect therapeutic outcome during treatment. The …

Aims and objectives Variations in drug metabolizing genes are known to have a clinical
impact on AED therapy. We genotyped normal and epileptic patient cohorts of monoethnic …

Purpose: The aim of this study was to clarify the effects of genetic polymorphisms of
cytochrome P450 (CYP) 2C9 and 2C19 on the metabolism of phenytoin (PHT). In addition, a …